The earnings call highlighted strong sales performance, successful international expansion, and robust financial health. However, challenges such as tariff impacts and increased operating expenses were noted. The positive developments, particularly the increased sales guidance and international growth, outweigh the lowlights, indicating resilience and growth potential.

Company Guidance -

Q3 2025

In the LeMaitre Vascular Q1 2025 earnings call, the company revised its full-year sales guidance upward to $245 million from the previous $239 million, driven by a strong 13% organic sales growth compared to the prior guidance of 10%. The growth was propelled by increased sales across all product categories, including a 17% rise in grafts and a 14% increase in carotid shunts. Geographically, EMEA sales surged by 18%, while the Americas and APAC saw increases of 11% and 3%, respectively. LeMaitre also expanded its salesforce, aiming to reach 170 representatives by year-end, up from the current 164, and is bolstering its international presence with new sales offices. The gross margin for Q1 was 69.2%, slightly up from the previous year, driven primarily by a 9% increase in average selling prices. Operating income grew by 6% year-over-year to $12.6 million, resulting in an operating margin of 21%. The company also highlighted its strategic optionality with $303 million in cash, despite challenges such as tariffs and the cessation of its Elutia distribution agreement impacting its financial outlook.

Strong Sales Performance

Q1 sales were stronger than February 27 guidance with 13% organic growth and 12% reported growth. Record sales were achieved in all five categories: graphs, carotid shunts, catheters, velvet homes, and patches.

International Expansion and Regulatory Success

Established new international sales offices and received MDR CE mark for autographs. European launch imminent with additional approvals expected in Australia, Canada, Singapore, and Korea by H1 2026.

Increased Sales Guidance

Raised 2025 reported sales guidance to $245 million from $239 million. Organic sales guidance increased to 13% from 10%.

Strong Financial Position

Ended Q1 with $302.5 million in cash and securities, providing strategic optionality. Cash from operations generated $9 million in the quarter.

Positive Price and Volume Dynamics

Organic sales growth driven by 9% average selling price increases and 4% unit increases. Gross margin improved by 60 basis points year over year.

Lemaitre Vascular (LMAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LMAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.57 / -	0.49	―	―	―
Aug 05, 2025	2025 (Q2)	0.57 / 0.60	0.52	15.38% (+0.08)	―
May 01, 2025	2025 (Q1)	0.50 / 0.48	0.44	9.09% (+0.04)	―
Feb 27, 2025	2024 (Q4)	0.49 / 0.49	0.38	28.95% (+0.11)
Oct 31, 2024	2024 (Q3)	0.43 / 0.49	0.33	48.48% (+0.16)
Aug 01, 2024	2024 (Q2)	0.47 / 0.52	0.36	44.44% (+0.16)
May 02, 2024	2024 (Q1)	0.39 / 0.44	0.27	62.96% (+0.17)
Feb 27, 2024	2023 (Q4)	0.36 / 0.38	0.25	52.00% (+0.13)
Nov 01, 2023	2023 (Q3)	0.31 / 0.33	0.25	32.00% (+0.08)	―
Aug 01, 2023	2023 (Q2)	0.32 / 0.36	0.16	125.00% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LMAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$85.60	―	―
May 01, 2025	$90.02	$78.51	-12.79%
Feb 27, 2025	$99.42	$91.40	-8.07%
Oct 31, 2024	$87.82	$94.27	+7.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lemaitre Vascular (LMAT) report earnings?

Lemaitre Vascular (LMAT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Lemaitre Vascular (LMAT) earnings time?

Lemaitre Vascular (LMAT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LMAT EPS forecast?

LMAT EPS forecast for the fiscal quarter 2025 (Q3) is 0.57.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing